Латанопрост в терапии первичной открытоугольной глаукомы
https://doi.org/10.21516/2072-0076-2024-17-4-141-147
Аннотация
Латанопрост, аналог простагландинов класса F2α, присутствует на рынке местных гипотензивных средств для терапии глаукомы и офтальмогипертензии почти 30 лет, являясь препаратом первого выбора благодаря высокой эффективности, хорошей переносимости и минимальной дозировке. Препарат эффективен во всех возрастных группах и разрешен в педиатрической практике от 1 года. По данным многочисленных исследований, монотерапия латанопростом позволяет снижать офтальмотонус в среднем на 22–39 % от исходного уровня в течение нескольких лет, снижения гипотензивного эффекта со временем не отмечено. Латанопрост совместим со всеми другими группами антиглаукомных препаратов, демонстрирует аддитивный эффект.
При поддержке: никто из авторов не имеет финансовой заинтересованности в представленных материалах или методах
Об авторах
С. Ю. Петров
ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России
Россия
Россия
Сергей Юрьевич Петров — д-р мед. наук, начальник отдела глаукомы.
Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062
О. И. Маркелова
ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России
Россия
Россия
Оксана Игоревна Маркелова — аспирант.
Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062
Список литературы
1. Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. Cyclooxygenase pathways. Acta Biochim Pol. 2014; 61 (4): 639–49. PMID: 25343148.
2. Euler V. Über die Spezifische Blutdrucksenkende Substanz des Menschlichen Prostata- und Samenblasensekretes. Klin Wochenschr. 1935; 14: 1182–3. https://doi.org/10.1007/BF01778029
3. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004; 103 (2): 147–66. doi: 10.1016/j.pharmthera.2004.06.003
4. Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014; 30 (2–3): 102–9. doi: 10.1089/jop.2013.0179
5. Angeli A, Supuran CT. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013-2018). Expert Opin Ther Pat. 2019; 29 (10): 793–803. doi: 10.1080/13543776.2019.1661992
6. Aihara M. Prostanoid receptor agonists for glaucoma treatment. Jpn J Ophthalmol. 2021; 65 (5): 581–90. doi: 10.1007/s10384-021-00844-6
7. Davis T.L., Sharif N.A. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J Ocul Pharmacol Ther. 1999; 15 (4): 323–36. doi: 10.1089/jop.1999.15.323
8. Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002 May; 43 (5): 1475–87. PMID: 11980863.
9. Sharif NA, Davis TL, Williams GW. [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol. 1999; 51 (6): 685–94. doi: 10.1211/0022357991772989
10. Park JH, Yoo C, Chung HW, Kim YY. Effect of prostaglandin analogues on anterior scleral thickness and corneal thickness in patients with primary open-angle glaucoma. Sci Rep. 2021; 11 (1): 11098. doi: 10.1038/s41598-021-90696-4
11. Tripathy K, Geetha R. Latanoprost: Treasure Island; 2022.
12. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003; 44 (2): 715–21. doi: 10.1167/iovs.02-0323
13. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989; 48 (5): 707–16. doi: 10.1016/0014-4835(89)90011-0
14. Stjernschantz J, Selen G, Sjoquist B, Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res. 995; 23: 513–8. PMID: 7732899.
15. Stjernschantz J., Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol. 1996; 7 (2): 11–7. doi: 10.1097/00055735-199604000-00003
16. Walters TR, DuBiner HB, Carpenter SP, Khan B. VanDenburgh AM, Bimatoprost Circadian I.O.P.S.G. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004; 49 Suppl 1: S26-35. doi: 10.1016/j.survophthal.2003.12.017
17. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989; 49 (3): 389–402. doi: 10.1016/0014-4835(89)90049-3
18. Giuffre G. The effects of prostaglandin F2 alpha in the human eye. Graefes Arch Clin Exp Ophthalmol. 1985; 222 (3): 139–41. doi: 10.1007/BF02173538
19. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993; 100 (9): 1297–304. doi: 10.1016/s0161-6420(93)31484-3
20. Bill A. Conventional and uveo-scleral drainage of aqueous humour in the cynomolgus monkey (Macaca irus) at normal and high intraocular pressures. Exp Eye Res. 1966; 5 (1): 45–54. doi: 10.1016/s0014-4835(66)80019-2
21. Bill A. Uveoscleral drainage of aqueous humor: physiology and pharmacology. Prog Clin Biol Res. 1989; 312: 417–27
22. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993; 111 (10): 1351–8. doi: 10.1001/archopht.1993.01090100059027
23. Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002; 47 Suppl 1: S6–12. doi: 10.1016/s0039-6257(02)00302-8
24. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018; 96 (3): e277-e84. doi: 10.1111/aos.13568
25. Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology. 2016; 123 (1): 129–40. doi: 10.1016/j.ophtha.2015.09.005
26. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014; 311 (18): 1901–11. doi: 10.1001/jama.2014.3192
27. European Glaucoma Society. Terminology and guidelines for glaucoma. 5th edition ed: Savona, Italy PubliComm; 2020.
28. Basic and Clinical Science Course. 10. Glaucoma. 2022.
29. Клинические рекомендации «Глаукома первичная открытоугольная» 2020 (16.02.2021), утверждены Минздравом РФ.
30. Natale RD. Trends and discrepancies in glaucoma medical therapy in Europe. European Ophthalmic Review. 2015; 9 (2): 130–1. doi: 10.17925/EOR.2015.09.02.130
31. Fajgenbaum M, Ansari E. Prescribing trends in a glaucoma clinic and adherence to EGS guidelines: A retrospective, non-interventional, single-center UK study. Adv Ther. 2017; 34 (8): 2033–42. doi: 10.1007/s12325-017-0593-9
32. Diestelhorst M, Krieglstein GK, Lusky M, Nagasubramanian S. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue. Surv Ophthalmol. 1997; 41 Suppl 2: S77–81. doi: 10.1016/s0039-6257(97)80011-2
33. Fristrom B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993; 111 (5): 662–5. doi: 10.1001/archopht.1993.01090050096037
34. Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging. 1996; 9 (5): 363–78. doi: 10.2165/00002512-199609050-00007
35. Upjohn P. Xalatan (latanoprost ophthalmic solution): prescribing information. 2002.
36. DuBiner HB, Mroz M, Shapiro AM, Dirks MS, Brimonidine vs. Latanoprost Study G. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther. 2001; 23 (12): 1969–83. doi: 10.1016/s0149-2918(01)80150-8
37. Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol. 2000; 238 (1): 19–23. doi: 10.1007/s004170050003
38. Jampel HD, Bacharach J, Sheu WP, et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol. 2002; 134 (6): 863–71. doi: 10.1016/s0002-9394(02)01820-2
39. Kampik A, Arias-Puente A, O'Brart DP, Vuori ML, European Latanoprost Study G. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma. 2002; 11 (2): 90–6. doi: 10.1097/00061198-200204000-00003
40. Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005 % once daily versus brimonidine 0.2 % twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001; 131 (5): 631–5. doi: 10.1016/s0002-9394(00)00902-8
41. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385 (9975): 1295–304. doi: 10.1016/S0140-6736(14)62111-5
42. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005 % latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995; 102 (12): 1743–52. doi: 10.1016/s0161-6420(95)30798-1
43. Aquino MV, Chew PT, Aung T, Rojanapongpun P, Group E.S. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology. 2004; 111 (3): 427–34. doi: 10.1016/j.ophtha.2003.06.007
44. Aung T, Chew PT, Yip CC, et al. A randomized double-masked crossover study comparing latanoprost 0.005 % with unoprostone 0.12 % in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001; 131 (5): 636–42. doi: 10.1016/s0002-9394(00)00943-0
45. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996; 103 (11): 1916–24. doi: 10.1016/s0161-6420(96)30407-7
46. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001; 45 Suppl 4: S353–60. doi: 10.1016/s0039-6257(01)00212-0
47. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM, Bimatoprost Study G. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001; 18 (3): 110–21. doi: 10.1007/BF02850299
48. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 1996; 114 (8): 929–32. doi: 10.1001/archopht.1996.01100140137004
49. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001; 132 (4): 472–84. doi: 10.1016/s0002-9394(01)01177-1
50. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group. Br J Ophthalmol. 2000; 84 (6): 579–82. doi: 10.1136/bjo.84.6.579
51. Saito M, Takano R, Shirato S. Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma. Am J Ophthalmol. 2001; 132 (4): 485–9. doi: 10.1016/s0002-9394(01)01096-0
52. Susanna R Jr, Giampani J Jr, Borges AS, Vessani RM, Jordao M.L. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001; 108 (2): 259–63. doi: 10.1016/s0161-6420(00)00495-4
53. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996; 103 (1): 126–37. doi: 10.1016/s0161-6420(96)30750-1
54. Denis P, Baudouin C, Bron A, et al. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol. 2010; 10: 4. doi: 10.1186/1471-2415-10-4
55. Alm A, Widengard I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 2000; 78 (1): 71–6. doi: 10.1034/j.1600-0420.2000.078001071.x
56. Suzuki M, Mishima HK, Masuda K, et al. Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan. Jpn J Ophthalmol. 2000; 44 (1): 33–8. doi: 10.1016/s0021-5155(99)00147-1
57. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998; 105 (1): 82–7. doi: 10.1016/s0161-6420(98)91372-0
58. Konstas AG, Maltezos AC, Gandi S, Hudgins AC, Stewart WC. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol. 1999; 128 (1): 15–20. doi: 10.1016/s0002-9394(99)00073-2
59. Larsson LI. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005 % or timolol gel-forming solution 0.5 % in patients with ocular hypertension. Ophthalmology. 2001; 108 (8): 1439–44. doi: 10.1016/s0161-6420(01)00605-4
60. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000; 41 (9): 2566–73. PMID: 10937568.
61. Camras CB, Sheu WP, United States Latanoprost-Brimonidine Study G. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma. 2005; 14 (2): 161–7. doi: 10.1097/01.ijg.0000151881.99607.4e
62. Einarson TR, Kulin NA, Tingey D, Iskedjian M. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clin Ther. 2000; 22 (12): 1502–15. doi: 10.1016/s0149-2918(00)83048-9
63. Lumigan. EMEA Scientific Discussion Document (CPMP/and ocular hypertension patients uncontrolled on β-blockers: 3819/02) [online]. Available from URL:http://tolerance and peak intraocular pressure lowering. Alphagen/www.emea.eu.int [Accessed 2003 Mar 19].
64. Garcia Sanchez J, The Spanish Latanoprost Study Group A. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension - A three-month randomised study. Eur J Ophthalmol. 2000; 10 (3): 198–204. doi: 10.5301/EJO.2008.5687
65. Honrubia FM, Larsson LI, Spiegel D, European latanoprost study G. A comparison of the effects on intraocular pressure of latanoprost 0.005 % and the fixed combination of dorzolamide 2 % and timolol 0.5 % in patients with open-angle glaucoma. Acta Ophthalmol Scand. 2002; 80 (6): 635–41. doi: 10.1034/j.1600-0420.2002.800615.x
66. Italian Multicentric Open Randomized Study under the aegis of A.I.S.G.F.R., Official R. Hypotensive efficacy in primary open-angle glaucoma and ocular hypertension: latanoprost in monotherapy vs timolol and dorzolamide in association. Acta Ophthalmol Scand Suppl. 2000; 232: 49–50. doi: 10.1111/j.1600-0420.2000.tb01102.x
67. Polo V, Larrosa JM, Gomez ML, Pablo L, Honrubia FM. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol Scand. 2001; 79 (1): 6–9. doi: 10.1034/j.1600-0420.2001.079001006.x
68. Pillunat LE, Larsson LI, European, Canadian Latanoprost Study G. Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma. Br J Ophthalmol. 2003; 87 (12): 1492–6. doi: 10.1136/bjo.87.12.1492
69. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997; 41 Suppl 2: S105-10. doi: 10.1016/s0039-6257(97)80016-1
70. Susanna R Jr, Medeiros FA. The pros and cons of different prostanoids in the medical management of glaucoma. Curr Opin Ophthalmol. 2001; 12 (2): 149–56. doi: 10.1097/00055735-200104000-00012
71. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997; 41 Suppl 2 (S129–38). doi: 10.1016/s0039-6257(97)80020-3
72. Grierson I, Lee WR, Albert DM. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol. 1999; 117 (3): 394–6. doi: 10.1001/archopht.117.3.394
73. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997; 124 (4): 544–7. doi: 10.1016/s0002-9394(14)70870-0
74. Demitsu T, Manabe M, Harima N, et al. Hypertrichosis induced by latanoprost. J Am Acad Dermatol. 2001; 44 (4): 721–3. doi: 10.1067/mjd.2001.111625
75. Parrish RK, Palmberg P, Sheu WP, Group X.L.T.S. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135 (5): 688–703. doi: 10.1016/s0002-9394(03)00098-9
76. Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye (Lond). 2012; 26 (11): 1465–72. doi: 10.1038/eye.2012.195
77. Oddone F, Scorcia V, Iester M, et al. Treatment of open-angle glaucoma and ocular hypertension with the fixed-dose combination of preservative-free Tafluprost/Timolol: Clinical outcomes from ophthalmology clinics in Italy. Clin Ophthalmol. 2022; 16: 1707–19. doi: 10.2147/OPTH.S364880
78. Karslioglu MZ, Hosal MB, Tekeli O. Periocular changes in topical bimatoprost and latanoprost use. Turk J Med Sci. 2015; 45 (4): 925–30. PMID: 26422869.
79. Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res. 2007; 32 (12): 1037–43. doi: 10.1080/02713680701750625
80. Ung T, Currie ZI. Periocular changes following long-term administration of latanoprost 0.005 %. Ophthalmic Plast Reconstr Surg. 2012; 28 (2): e42–4. doi: 10.1097/IOP.0b013e31821d86a5
81. Wand M, Ritch R, Isbey EK Jr, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol. 2001; 119 (4): 614–5.
82. Hatanaka M, Vessani prostamide RM, Elias IR, Morita C, Susanna RJr. The effect of prostaglandin analogs and on central corneal thickness. J Ocul Pharmacol Ther. 2009; 25 (1): 51–3. doi: 10.1089/jop.2007.0125
83. Schlote T, Tzamalis A, Kynigopoulos M. Central corneal thickness during treatment with travoprost 0.004 % in glaucoma patients. J Ocul Pharmacol Ther. 2009; 25 (5): 459–62. doi: 10.1089/jop.2009.0007
84. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004; 81 (8): 574–7. doi: 10.1097/01.opx.0000141791.16683.4a
85. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011; 55 (1): 22–7. doi: 10.1007/s10384-010-0904-z
86. Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013; 22 (8): 626–31. doi: 10.1097/IJG.0b013e31824d8d7c
87. Казанова С.Ю. Побочные эффекты аналогов простагландинов, используемых в офтальмологической практике. Российский офтальмологический журнал. 2021; 14 (2): 85–9. https://doi.org/10.21516/2072-0076-2021-14-2-85-89
88. Filippopoulos T, Paula JS, Torun N. Periorbital changes associated with topical bimatoprost. Ophthalmic Plast Reconstr Surg. 2008; 24 (4): 302–7. doi: 10.1097/IOP.0b013e31817d81df
89. Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013; 8 (5): e61638. doi: 10.1371/journal.pone.0061638
90. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998; 105 (2): 263–8. doi: 10.1016/s0161-6420(98)92977-3
91. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998; 126 (4): 602–4. doi: 10.1016/s0002-9394(98)00127-5
92. Lima MC, Paranhos AJr, Salim S, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000; 9 (4): 317–21. doi: 10.1097/00061198-200008000-00006
93. Wand M, Gaudio AR, Shields MB. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes. J Cataract Refract Surg. 2001; 27 (9): 1397–401. doi: 10.1016/s0886-3350(01)00770-2
94. Hollo G, Aung T, Cantor LB, Aihara M. Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management. Surv Ophthalmol. 2020; 65 (5): 496–512. doi: 10.1016/j.survophthal.2020.02.004
95. Hu J, Vu JT, Hong B, Gottlieb C. Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2020; 104 (8): 1040–4. doi: 10.1136/bjophthalmol-2019-315280
96. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999; 77 (6): 668–72. doi: 10.1034/j.1600-0420.1999.770612.x
97. Sacca S, Pascotto A, Siniscalchi C, Rolando M. Ocular complications of latanoprost in uveitic glaucoma: three case reports. J Ocul Pharmacol Ther. 2001; 17 (2): 107–13. doi: 10.1089/10807680151125393
98. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998; 126 (1): 37–41. doi: 10.1016/s0002-9394(98)00071-3
99. Hedner J, Everts B, Moller CS. Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. Arch Ophthalmol. 1999; 117 (10): 1305–9. doi: 10.1001/archopht.117.10.1305
Рецензия
Для цитирования:
Петров С.Ю., Маркелова О.И. Латанопрост в терапии первичной открытоугольной глаукомы. Российский офтальмологический журнал. 2024;17(4):141-147. https://doi.org/10.21516/2072-0076-2024-17-4-141-147
For citation:
Petrov S.Yu., Markelova O.I. Latanoprost in the treatment of primary open-angle glaucoma. Russian Ophthalmological Journal. 2024;17(4):141-147. https://doi.org/10.21516/2072-0076-2024-17-4-141-147
Просмотров:
448
Послать статью по эл. почте 